{"id":"https://genegraph.clinicalgenome.org/r/278b75c5-46f5-47fb-a259-f85858b54f90v1.0","type":"EvidenceStrengthAssertion","dc:description":"RAC2 was first reported in relation to autosomal dominant immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia in 2019 (Hsu AP et al., PMID: 30723080). This phenotypically heterogeneous disease is characterized by immunological defects (e.g., decreased B and T lymphopenia, T-cell and neutrophil disfunction, and hypogammaglobulinemia, including reduced IgM, IgA, and IgG) and recurrent and/or severe infections (particularly respiratory infections, but other types of infection, such as cellulitis, meningitis, and sepsis, have been reported). This disease has an age of onset of infancy or early childhood and incomplete penetrance has not been reported to date. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in the molecular mechanisms, inheritance pattern, and/or phenotypic variability. Therefore, the following disease entities have been split into multiple disease entities, autosomal dominant neutrophil immunodeficiency syndrome (i.e., autosomal dominant immunodeficiency 73a with defective neutrophil chemotaxis and lymphopenia; OMIM: # 608203), autosomal dominant immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia (OMIM: # 618986), and autosomal recessive immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia (OMIM: # 618987). The split curations for  autosomal dominant immunodeficiency 73a with defective neutrophil chemotaxis and lymphopenia and autosomal recessive immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia have been curated separately. Four missense variants that have been reported in 8 probands in 5 publications (PMIDs: 30654050, 30723080, 31071452, 31382036, 31919089) are included in this curation.  When family members were available to be genotyped, the variants were found to either be de novo (PMID: 30723080) or inherited from affected family members (PMID: 30654050, 31382036, 31919089). The mechanism of pathogenicity appears to be gain-of-function, as evidenced by an increased reactive oxygen species production and/or proportion of GTP-bound RAC2 (the active form) in the presence of these RAC2 variant, although there are concurrent defects in B-cell, T-cell, and neutrophil populations and/or functions. This gene-disease association is also supported by RAC2 expression being specific to hematopoietic cells and demonstrated roles for RAC2 in regulation of T cell proliferation, B cell survival and proliferation, and neutrophil effector functions, including reactive oxygen species production and chemotaxis (PMID: 2189110, 11581314, 14564009, 14564011). A mouse model expressing a gain-of-function variant reported in a patient was found to recapitulate the immunological features of the disease seen in humans (PMIDs: 30723080). Assessment of patient neutrophils carrying a RAC2 variant revealed significantly increased reactive oxygen species production and proportion of GTP-bound RAC2 and defects in chemotaxis and killing of Staphylococcus aureus compared to control neutrophils (PMID: 30723080, 31382036). In summary, there is strong evidence to support the relationship between RAC2 and autosomal dominant immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia. Three years must elapse from the first proposal of the association to reach a definitive classification without any valid contradictory evidence. We will re-evaluate this gene-disease relationship at that time to determine if an upgraded classification of definitive is warranted.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/278b75c5-46f5-47fb-a259-f85858b54f90","GCISnapshot":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3","calculatedEvidenceStrength":"Strong","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2021-11-28T02:56:47.456Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2021-10-19T15:55:22.241Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2be39c00-856f-4e91-8597-76094855f459","type":"EvidenceLine","dc:description":"Missense variant identified in patient, as well as affected father and grandfather. This appears to be a recurrent gain-of-function variant in RAC2. Previous functional analysis of variant indicates functional alternation (as well as work in this paper, but may use data in experimental section for scoring), particularly a potential gain-of-function for certain cell/effector functions.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2be39c00-856f-4e91-8597-76094855f459_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"This variant has been seen previously. Based on previous data, the presence of variant (RAC2 variant-carrying plasmid transfected into COS-7 cells) resulted in increased reactive oxygen stimulation following PMA stimulation compared to wild-type and negative control (Fig. 3B). Specifically, COS-7 cells were transfected with NADPH oxidase components (gp91phox, p47phox, p67phox) and either RAC2[WT], RAC2[E62K], or GFP and left unstimulated or stimulated with PMA. There was also increased phosphorylation in a downstream signal pathway member, Akt, in the presence of the variant. Specifically,COS-7 cells transfected with RAC2[WT], RAC2[E62K], or left untransfected were immunoblotted and stained for total AKT (tAKT) or phospho-AKT (S473), and the RAC2[E62K]-expressing cells had significantlty more p-Akt/Akt than the other cell types (from PMID: 30723080)\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2be39c00-856f-4e91-8597-76094855f459_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31382036","allele":{"id":"https://genegraph.clinicalgenome.org/r/0769fe2e-56a4-4e1c-893c-8af688931ff0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002872.5(RAC2):c.184G>A (p.Glu62Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA411443397"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ce8c3cd3-8d18-40d4-a419-e0b8b9f7974a","type":"EvidenceLine","dc:description":"De novo missense variant identified in patient, where it is unknown if parental identity was confirmed. Functional analysis of variant indicates functional alternation, particularly a potential gain-of-function for certain cell/effector functions. Absent from general population (gnomAD v2).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce8c3cd3-8d18-40d4-a419-e0b8b9f7974a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Presence of variant (RAC2 variant-carrying plasmid transfected into COS-7 cells) resulted in increased reactive oxygen stimulation following PMA stimulation compared to wild-type and negative control (Fig. 3B). Specifically, COS-7 cells were transfected with NADPH oxidase components (gp91phox, p47phox, p67phox) and either RAC2[WT], RAC2[E62K], or GFP and left unstimulated or stimulated with PMA. There was also increased phosphorylation in a downstream signal pathway member, Akt, in the presence of the variant. Specifically,COS-7 cells transfected with RAC2[WT], RAC2[E62K], or left untransfected were immunoblotted and stained for total AKT (tAKT) or phospho-AKT (S473), and the RAC2[E62K]-expressing cells had significantlty more p-Akt/Akt than the other cell types.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ce8c3cd3-8d18-40d4-a419-e0b8b9f7974a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30723080","allele":{"id":"https://genegraph.clinicalgenome.org/r/0769fe2e-56a4-4e1c-893c-8af688931ff0"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc857837-62ac-46c9-9e83-818b6e13cd2e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30654050","rdfs:label":"Family A","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/cc857837-62ac-46c9-9e83-818b6e13cd2e","type":"Family","rdfs:label":"Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/823e405e-34fd-4e76-8639-5974e8797e55","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30654050","rdfs:label":"P2","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":7,"allele":{"id":"https://genegraph.clinicalgenome.org/r/34acb0db-ac7f-4217-a5ad-6f6338b9b0b7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002872.5(RAC2):c.101C>A (p.Pro34His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/977224"}},"detectionMethod":"Whole exome sequencing was performed on the affected father and his two affected daughters.  The identified RAC2 variant was confirmed by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"WBCs (103 cells/mL) 1.640 (5.4-9.7), Neutrophils (103 cells/mL) 0.730 (2.5-5.9), Lymphocytes (103 cells/mL) 0.350 (1.28-2.76), Monocytes (103 cells/mL) 0.172 (0.19-0.81), Platelets (103 cells/mL) 214 (187-367), CD3+ (103 cells/mL) 248 (1400-3700), CD3+CD4+ (103 cells/mL) 140 (700-2200), CD3+CD8+ (103 cells/mL) 55 (490-1300), CD3â€“ CD56+ (103 cells/mL) 56 (130-0.720), IgG (mg/dL) 353 (463-1236), IgM (mg/dL) 14 (43-196), IgA (mg/dL) 17 (25-154),Tetanus vaccine titer undetectable, Hepatitis vaccine titer undetetable","phenotypes":["obo:HP_0002720","obo:HP_0002850","obo:HP_0004315","obo:HP_0030253","obo:HP_0040218","obo:HP_0001888","obo:HP_0012312","obo:HP_0010976","obo:HP_0005403","obo:HP_0410294","obo:HP_0001875","obo:HP_0005425"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a7ed0ccd-cf35-471c-b9b0-e3ed17882573_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30654050","allele":{"id":"https://genegraph.clinicalgenome.org/r/34acb0db-ac7f-4217-a5ad-6f6338b9b0b7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0010976","obo:HP_0001875","obo:HP_0005403","obo:HP_0030253","obo:HP_0001888","obo:HP_0005425"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/823e405e-34fd-4e76-8639-5974e8797e55"}},{"id":"https://genegraph.clinicalgenome.org/r/f30f1aa0-9386-4275-ab6a-2b5cd57c01c6_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31919089","rdfs:label":"Kindred 2","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/f30f1aa0-9386-4275-ab6a-2b5cd57c01c6","type":"Family","rdfs:label":"Kindred 2","member":{"id":"https://genegraph.clinicalgenome.org/r/2fa6d861-eba5-41dc-a26e-b832eb8c551a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31919089","rdfs:label":"P2","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":10,"allele":{"id":"https://genegraph.clinicalgenome.org/r/72c247e8-fb06-435d-9e48-8c246a3b0744","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002872.5(RAC2):c.34G>A (p.Gly12Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA411444096"}},"detectionMethod":"Genomic DNA was derived from fibroblasts from the affected proband (P2) and affected proband's daughter (P3) and peripheral blood monocytes from the unaffected P3's father and then sequenced by whole exome sequencing.  RAC2 G12R was identified in P2 and P3, but not the father, and confirmed by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0005528","obo:HP_0002090","obo:HP_0001888","obo:HP_0005403","obo:HP_0010976","obo:HP_0012312","obo:HP_0001875","obo:HP_0100806"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/97b4ac6c-9cd3-48be-ac7e-f0c061cd49be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31919089","allele":{"id":"https://genegraph.clinicalgenome.org/r/72c247e8-fb06-435d-9e48-8c246a3b0744"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0005403","obo:HP_0001888","obo:HP_0012312","obo:HP_0010976","obo:HP_0001875","obo:HP_0100806","obo:HP_0005528"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2fa6d861-eba5-41dc-a26e-b832eb8c551a"}},{"id":"https://genegraph.clinicalgenome.org/r/cf1e10c3-c638-4991-8b02-eceb8df5e272_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31382036","rdfs:label":"Family A","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/cf1e10c3-c638-4991-8b02-eceb8df5e272","type":"Family","rdfs:label":"Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/ac14ae48-08b7-4436-bf37-41b67cb4981a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31382036","rdfs:label":"P1","allele":{"id":"https://genegraph.clinicalgenome.org/r/0769fe2e-56a4-4e1c-893c-8af688931ff0"},"detectionMethod":"NGS-based immunodeficiency panel analysis showed a heterozygous variant c. 184G>A. Variant identified in grandfather, father, and proband, all of whom were affected. ","firstTestingMethod":"Next generation sequencing panels","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2be39c00-856f-4e91-8597-76094855f459_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"P1 had suffered from respiratory tract infections\n(RTIs) requiring treatment with oral antibiotics. P2 and P3 had suffered\nfrom similar recurrent RTIs causing pulmonary damage leading to endstage\npulmonary failure for which they both required lung transplantation;\nP3 passed away during this procedure. Lymphocyte phenotyping\nof P1 and P2 showed T-cell and B-cell lymphopenia with high relative\npercentages of effector/memory T-cells (Supplementary Table S1),\nwithout bone marrow abnormalities. This differed from previously\nencountered RAC2 mutations, which did not present with an absolute\nCID nor with end-stage pulmonary failure","phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0032184","obo:HP_0010976","obo:HP_0005403","obo:HP_0002783"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ac14ae48-08b7-4436-bf37-41b67cb4981a"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2c1d4e43-8482-435e-85c3-4d5378e27916","type":"EvidenceLine","dc:description":"This missense variant is absent from the general population (gnomAD v2) and its pathogenicity is supported by functional evidence. The functional phenotype recapitulates that seen for neutrophils in patients carrying other RAC2 gain-of-function variants, include increased ROS production (e.g., PMID: 30723080). ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2c1d4e43-8482-435e-85c3-4d5378e27916_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Neutrophils from patient heterozygous for RAC2 variant displayed decreased chemotaxis compared to control neutrophils in response to fMLF (Fig. 1C). Patient neutrophils also contained large vacuoles not observed in control (Fig. 1E). Expression of RAC2 N92T in HEK293 transfected with NADPH oxidase components resulted in a notable increase in both basal and PMA-stimulated reactive oxygen species production compared to WT RAC-expressing HEK293 cells, which is consistent with an increased proportion of GTP-bound RAC2 (Fig. 1D). ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2c1d4e43-8482-435e-85c3-4d5378e27916_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31071452","allele":{"id":"https://genegraph.clinicalgenome.org/r/1df692a7-bf73-4a48-ac60-ce881a56a80f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002872.5(RAC2):c.275A>C (p.Asn92Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/977225"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0e43362e-20bc-49ee-8e9f-e5a30c3d71d5","type":"EvidenceLine","dc:description":"Missense variant detected in patient with pathogenicity being supported by functional studies and being absent from the general population (gnomAD v2).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0e43362e-20bc-49ee-8e9f-e5a30c3d71d5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC2 carrying the variant was found to be more active than WT RAC2 based on a significant increase in GTP-bound RAC2 in HEK293 cells transfected with RAC2 G12R vs. those transfected with WT RAC2 (Fig. 1E). Notably, the levels of GTP-bound RAC2 in cells expressing RAC2G12R were similar to levels expressing a constitutively active form of RAC2, G12V.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0e43362e-20bc-49ee-8e9f-e5a30c3d71d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31919089","allele":{"id":"https://genegraph.clinicalgenome.org/r/72c247e8-fb06-435d-9e48-8c246a3b0744"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/97b4ac6c-9cd3-48be-ac7e-f0c061cd49be","type":"EvidenceLine","dc:description":"Missense variant with pathogenicity supported by functional analysis and being absent from general population (gnomAD v2).  Functional analysis indicates this is a gain-of-function mutation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97b4ac6c-9cd3-48be-ac7e-f0c061cd49be_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RAC2 carrying the variant was found to be more active than WT RAC2 based on a significant increase in GTP-bound RAC2 in HEK293 cells transfected with RAC2 G12R vs. those transfected with WT RAC2 (Fig. 1E). Notably, the levels of GTP-bound RAC2 in cells expressing RAC2G12R were similar to levels expressing a constitutively active form of RAC2, G12V.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/97b4ac6c-9cd3-48be-ac7e-f0c061cd49be_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fec2162c-ae57-42cb-be69-172f7dd57a2a","type":"EvidenceLine","dc:description":"De novo missense variant identified in patient, where it is unknown if parental identity was confirmed. Functional analysis of variant indicates functional alternation, particularly a potential gain-of-function for certain cell/effector functions.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fec2162c-ae57-42cb-be69-172f7dd57a2a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Presence of variant (RAC2 variant-carrying plasmid transfected into COS-7 cells) resulted in increased reactive oxygen stimulation following PMA stimulation compared to wild-type and negative control (Fig. 3B). Specifically, COS-7 cells were transfected with NADPH oxidase components (gp91phox, p47phox, p67phox) and either RAC2[WT], RAC2[E62K], or GFP and left unstimulated or stimulated with PMA. There was also increased phosphorylation in a downstream signal pathway member, Akt, in the presence of the variant. Specifically,COS-7 cells transfected with RAC2[WT], RAC2[E62K], or left untransfected were immunoblotted and stained for total AKT (tAKT) or phospho-AKT (S473), and the RAC2[E62K]-expressing cells had significantlty more p-Akt/Akt than the other cell types.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/fec2162c-ae57-42cb-be69-172f7dd57a2a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30723080","allele":{"id":"https://genegraph.clinicalgenome.org/r/0769fe2e-56a4-4e1c-893c-8af688931ff0"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a7ed0ccd-cf35-471c-b9b0-e3ed17882573","type":"EvidenceLine","dc:description":"This missense variant segregated with disease within a single family, is absent from the general population (gnomAD v2), and has functional data supporting its pathogenicity, as well as it being a gain-of-function mutation (increased reactive oxygen species production in neutrophils and increased GTP-binding by RAC2 P34H).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7ed0ccd-cf35-471c-b9b0-e3ed17882573_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient neutrophils displayed increased reactive oxygen species production after fMLP stimulation (Fig. 1H). WT or RAC2 P34H were expressed in HEK293T, RAC2 was pulled down from these cells, and then tested for binding to a GST-PAK-PDB fusion protein, which indicates GTP-bound RAC2.  RAC2 P34H displayed increased GTP-binding compared to WT RAC2 (Fig. 1F). Both of these phenotypes are consistent with a functional defect and gain-of-function.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a7ed0ccd-cf35-471c-b9b0-e3ed17882573_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e293fb8-ac7b-4dcb-8777-f8e193ee8808","type":"EvidenceLine","dc:description":"De novo missense variant identified in patient, where it is unknown if parental identity was confirmed. Functional analysis of variant indicates functional alternation, particularly a potential gain-of-function for certain cell/effector functions.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e293fb8-ac7b-4dcb-8777-f8e193ee8808_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Presence of variant (RAC2 variant-carrying plasmid transfected into COS-7 cells) resulted in increased reactive oxygen stimulation following PMA stimulation compared to wild-type and negative control (Fig. 3B). Specifically, COS-7 cells were transfected with NADPH oxidase components (gp91phox, p47phox, p67phox) and either RAC2[WT], RAC2[E62K], or GFP and left unstimulated or stimulated with PMA. There was also increased phosphorylation in a downstream signal pathway member, Akt, in the presence of the variant. Specifically,COS-7 cells transfected with RAC2[WT], RAC2[E62K], or left untransfected were immunoblotted and stained for total AKT (tAKT) or phospho-AKT (S473), and the RAC2[E62K]-expressing cells had significantlty more p-Akt/Akt than the other cell types.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1e293fb8-ac7b-4dcb-8777-f8e193ee8808_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30723080","allele":{"id":"https://genegraph.clinicalgenome.org/r/0769fe2e-56a4-4e1c-893c-8af688931ff0"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":5.5},{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/205265da-e579-474c-9231-9908da574a23","type":"EvidenceLine","dc:description":"This mouse models recapitulates many aspects of disease in humans and human cells (smaller T and B cell populations and increased reactive oxygen species and F-actin production). However, the mice were not assessed for hypogammaglobulinemia or susceptibility to infection.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f3d1e5d2-4050-401a-bea9-d54d1d8a4e06","type":"Finding","dc:description":"Introduction of the variant into a mouse resulted in a significant reduction in the number of overall T cells, CD4+ T cells, CD8+ T cells, and B cells in the blood and increased reactive oxygen species production and F-actin expression. These phenotypes have been observed in patients, patient cells, and/or transfected cells carrying this RAC2 variant.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30723080","rdfs:label":"RAC2E62K mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3dc2ee78-c338-436e-96e2-f9a750649764","type":"EvidenceLine","dc:description":"Neutrophils isolated from patients heterozygous for RAC2 E62K were impaired at killing of neutrophils, which is suggestive of a contributing factor to increased susceptibility of patients to infection (along with other factors). ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1baac8b-7836-474e-bc25-1250da3d629d","type":"Finding","dc:description":"Patients carrying this variant, RAC2 E62K, present with recurrent infections, indicating impairment of the immune system.  This assay, which reveals that patient neutrophils (expressing RAC2 E62K) were defective at killing of GFP-expressing Staphylococcus aureus in vitro compared to healthy control neutrophils (Fig. 1D).  This is indicative of a potential additional mechanism of immunodeficiency, in addition to the T and B lymphopenia, that may be contributing to patient susceptibility to infection. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31382036","rdfs:label":"Bacterial killing by RAC2 E62K-expressing neutrophils","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fcc28ab7-aecf-458d-8649-9c32f55d6406","type":"EvidenceLine","dc:description":"Using patient neutrophils, the presence of the variant resulted in a defect in superoxide production and chemotaxis and an increase in F-actin production in response to stimulation, which RAC2 has previously been demonstrated to have a role in.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91ccb3f1-2577-4736-905b-41a24c1a1a71","type":"FunctionalAlteration","dc:description":"Neutrophils isolated from 2 unrelated patients carrying the RAC2E62K variant were compared to neutrophils from 6 healthy controls in terms of superoxide production 9both over time and cumulatively) in response to fMLF over time.  The variant carrying neutrophils from both patients generated significantly more reactive oxygen species than the healthy controls. Diogenes reagent and a plate reader were used to visualize/measure reactive oxygen species production. A defect in chemotaxis was also noted for patient neutrophils compared to healthy control neutrophils in response to fMLF. In addition, there was an increase in F-actin expression in patient neutrophils following stimulation with fMLP","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30723080","rdfs:label":"Neutrophils functions in cells with RAC2E62K"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ae097da1-8676-45b0-9d14-c35624b1f9ad","type":"EvidenceLine","dc:description":"Neutrophils isolated from patients carrying the RAC2 missense variant 184G>A displayed increased ratios of RAC2 GTP-binding in response to fMLF. This is consistent with a gain-of-function for this variant as the GTP-bound RAC2 is considered the active version of RAC2.  Notably, chemotaxis in patient neutrophils was impaired, recapitulating results seen in neutrophils from different patients carrying the same variant.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d08280d9-ced1-4b82-b806-e274c00b4f69","type":"FunctionalAlteration","dc:description":"There was an increased ratio of GTP-bound RAC2 to non-GTP bound RAC2 in the patient neutrophils compared to the control following stimulation with fMLF (Fig. 1B).  To measure this, RAC2 was immunoprecipitated using GTP-bound RAC2 with PAK-loaded beads (which bind specifically to the GTP-bound RAC2 vs non bound) and then ran on a gel. Notaby, a similar phenotype was noted for patient neutrophils in PMID: 30723080 carrying the same variant. In addition, Chemotaxis of neutrophils isolated from 2 patients (father and son from the same kindred) was assessed in fibrin gel following stimulation with fMLF.  The patient cells (carrying the RAC2 variant) displayed significantly less chemotaxis in the presence of fMLF than the control cells in terms of both chemotaxis velocity and distance (Fig. 1C). ]","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31382036","rdfs:label":"GTP binding by RAC2"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a6c1e0b1-de02-4899-9825-acc950bedcc3_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0de433e9-3c1f-4fa1-9690-d4947c56401c","type":"EvidenceLine","dc:description":"These experiments indicate RAC2 has a role in T cell proliferation.  Disruption of this function may be involved in the T cell population downsizing noted in patients with RAC2-associated disease. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2fea6400-9e93-4026-b136-7c29fd60d8ef","type":"Finding","dc:description":"A significant decrease in the T cell population has been observed in patients with RAC2-associated disease.  These experiments indicate RAC2 has a role in T cell proliferation and thus could be involved in the smaller population of T cells observed in patients. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11581314","rdfs:label":"RAC2 role in T cell proliferation","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/2cc83d85-3edb-498b-a868-366e2d316e3a","type":"EvidenceLine","dc:description":"Assessment of patient neutrophils has revealed changes in chemotaxis and reactive oxygen species production. These experiments support a role in RAC2 regulation of these processes in neutrophils.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/04263d5e-b355-48fb-b389-ccd7edda3569","type":"Finding","dc:description":"Assessment of patient neutrophils has revealed changes in chemotaxis and reactive oxygen species production. These experiments support a role in RAC2 regulation of these processes in neutrophils.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14564009","rdfs:label":"RAC2 role in neutrophil superoxide production and chemotaxis","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/311e08c2-265f-4979-90e5-f3340720f708","type":"EvidenceLine","dc:description":"Experimental studies with B cells demonstrate a role for RAC2 in B cell survival and proliferation, which is consistent with B cell defects seen in patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8475ef41-844f-4599-8d0c-9b2e5d95f0aa","type":"Finding","dc:description":"These experiments demonstrate a role for RAC2 in B cell proliferation and survival, which is consistent with the reduction in the B cell populations noted in these patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14564011","rdfs:label":"RAC2 role in B cell survival and proliferation","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1d699a52-35a0-4bd5-982f-add00964e928","type":"EvidenceLine","dc:description":"Patients with RAC2-associated disease show defects in neutrophil, T cell, and B-cell populations/functions.  Expression occurring in and being specific to hematopoietic cells is consistent with the patient phenotypes.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d98bcbe2-86a9-4b17-b05e-11b69a393789","type":"Finding","dc:description":"Northern blot analysis of different murine cell types and tissues with labeled RAC2 cDNA as the probe revealed RAC2 expression based on the presence of transcripts occurred in myeloid (Fig. 3), pre-B, B, T, and erythroleukemic cell lines (Fig. 4) and in the bone marrow, spleens, and thymus, but not in the brain, kidney, lung, liver, or testes (Fig. 5).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2189110","rdfs:label":"RAC2 expression specific to hematopoietic cells","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Strong","sequence":3693,"specifiedBy":"GeneValidityCriteria8","strengthScore":11.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/a6sffG48wbI","type":"GeneValidityProposition","disease":"obo:MONDO_0033554","gene":"hgnc:9802","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_a6c1e0b1-de02-4899-9825-acc950bedcc3-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}